Introduction: Obesity is increasingly recognized as a chronic, adiposity-based disease rather than a condition defined solely by body mass index (BMI). Recent guidelines from major international organizations have introduced new diagnostic frameworks that incorporate body fat distribution, metabolic dysfunction, and obesity-related complications.
Introduction:
Obesity is increasingly recognized as a chronic, adiposity-based disease rather than a condition defined solely by body mass index (BMI). Recent guidelines from major international organizations have introduced new diagnostic frameworks that incorporate body fat distribution, metabolic dysfunction, and obesity-related complications. This review synthesizes these contemporary recommendations and outlines their implications for clinical practice.
Why was this study needed?
. BMI alone inadequately reflects body fat distribution, metabolic risk, and organ dysfunction.
. New international guidelines propose differing approaches to obesity diagnosis and staging.
. Clinicians require a unified understanding of evolving obesity definitions and management strategies.
. A more individualized framework may improve risk stratification and treatment decisions.
Results:
The review highlights a paradigm shift from BMI-centric diagnosis to a multimodal assessment incorporating anthropometric measures, body composition, fat distribution, and obesity-related complications. Waist-based measurements are emphasized for identifying central adiposity and cardiometabolic risk across diverse populations. Across major society guidelines—including EASO, the Lancet Diabetes & Endocrinology Commission, ACC, and AACE—there is broad agreement that obesity should be viewed as a heterogeneous chronic disease characterized not only by excess adiposity but also by its clinical consequences, such as organ dysfunction and functional impairment. Although the guidelines differ in specific diagnostic criteria and staging systems, they consistently advocate comprehensive risk assessment and individualized management rather than reliance on BMI thresholds alone.
Clinical Impact:
These evolving frameworks encourage clinicians to move beyond BMI when diagnosing and managing obesity. Incorporating waist circumference, body composition assessment, and evaluation of obesity-related complications can improve identification of high-risk individuals, support more personalized treatment selection, and facilitate earlier intervention. Challenges remain regarding implementation, standardization, resource utilization, and determining eligibility for emerging obesity therapies.
Bottom Line:
Modern obesity guidelines redefine obesity as a chronic disease based on excess adiposity and its clinical consequences—not BMI alone—supporting a comprehensive, patient-centered approach to diagnosis, staging, and management.
Introduction: Fibrosis is the principal determinant of long-term outcomes in metabolic dysfunction–associated steatotic liver disease (MASLD). This large international Global-MASLD study evaluated clinical predictors of advanced fibrosis and assessed the prognostic value of noninvasive fibrosis...
Introduction: Noninvasive tests (NITs) have become central to the diagnosis and staging of metabolic dysfunction–associated steatotic liver disease (MASLD), reducing reliance on liver biopsy. However, most validation studies have been performed in selected populations, and...
Introduction: Identifying patients with at-risk metabolic dysfunction–associated steatohepatitis (MASH) is essential because they carry a substantially higher risk of cirrhosis, hepatocellular carcinoma, and liver-related mortality. Although liver biopsy remains the diagnostic standard, it is impractical...
Introduction: The transition from non alcoholic fatty liver disease (NAFLD) to the steatotic liver disease (SLD) nomenclature has redefined metabolic dysfunction–associated steatotic liver disease (MASLD) as the principal subtype. While studies in adults have shown...
Introduction: Accurate prediction of liver-related events (LREs) is essential for risk stratification and therapeutic decision-making in metabolic dysfunction–associated steatotic liver disease (MASLD). Although liver biopsy remains the reference standard for fibrosis assessment, vibration-controlled transient elastography...
Introduction: Obesity, insulin resistance, and metabolic dysfunction-associated steatotic liver disease (MASLD) are closely linked metabolic disorders with limited disease-modifying therapies. This study identifies CD59, traditionally known as a complement regulatory protein, as a previously unrecognized...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.